Dudley Capital Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.61M Buy
22,307
+26
+0.1% +$5.59K 2.24% 11
2026
Q1
$4.85M Buy
22,281
+70
+0.3% +$15.5K 2.14% 10
2025
Q4
$5.08M Buy
22,211
+29
+0.1% +$6.61K 2.21% 11
2025
Q3
$5.14M Sell
22,182
-195
-0.9% -$39.7K 2.31% 10
2025
Q2
$4.15M Sell
22,377
-59
-0.3% -$11K 2.07% 11
2025
Q1
$4.7M Sell
22,436
-619
-3% -$120K 2.46% 10
2024
Q4
$4.1M Buy
23,055
+28
+0.1% +$5.15K 2.06% 11
2024
Q3
$4.55M Buy
23,027
+5
+0% +$933 2.35% 10
2024
Q2
$3.95M Buy
23,022
+6
+0% +$994 2.19% 10
2024
Q1
$4.16M Sell
23,016
-194
-0.8% -$33.4K 2.43% 10
2023
Q4
$3.6M Buy
23,210
+106
+0.5% +$15.5K 2.29% 9
2023
Q3
$3.44M Buy
23,104
+248
+1% +$36.4K 2.42% 8
2023
Q2
$3.08M Sell
22,856
-1,222
-5% -$179K 2.07% 11
2023
Q1
$3.84M Buy
24,078
+313
+1% +$47.9K 2.61% 6
2022
Q4
$3.84M Buy
+23,765
New +$3.64M 2.69% 6

Other funds holding ABBV

Dudley Capital Management's ABBV Position: Q2 2026 in Review

Dudley Capital Management increased its AbbVie (ABBV) stake by 0.12% in Q2 2026, buying an estimated $5.59K and bringing the position to 22,307 shares worth $5.61M. The position accounts for 2.24% of the portfolio, ranked #11.

Dudley Capital Management first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Dudley Capital Management held 22,307 shares of AbbVie worth $5.61M as of Q2 2026.
  • Dudley Capital Management bought 26 AbbVie shares in Q2 2026, an estimated $5.59K.
  • AbbVie made up 2.24% of Dudley Capital Management's portfolio in Q2 2026, its #11 holding.
  • Dudley Capital Management first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
  • 2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Dudley Capital Management's 13F filing for Q2 2026, filed 27 Jul 2026.